Top

Published in:

Open Access 01-12-2024 | Research

Causal effect of gut microbiota on venous thromboembolism: a two-sample mendelian randomization study

Authors: Linfeng Xi, Hongyi Wang, Jie Du, Anqi Liu, Jianping Wang, Yifei Ni, Shuai Zhang, Wanmu Xie, Min Liu, Chen Wang

Published in: Thrombosis Journal | Issue 1/2024

Abstract

Background

The gut microbiota of venous thromboembolism (VTE) patients exhibited significant alterations. However, the causal relationship between gut microbiota and VTE has not been fully understood. This study aimed to assess the causal relationship between gut microbiota and the risk of VTE using a two-sample Mendelian Randomization (MR) study.

Methods

The gut microbiota and VTE genetic data were collected from the MiBioGen consortium and the UK biobank, respectively. The potential causal relationship between gut microbiota and VTE was investigated using a two-sample MR analysis, including inverse variance weighted (IVW), weighted median, MR-Egger, simple mode, and weighted mode methods. Cochran’s Q-test, MR-PRESSO, and MR-Egger regression intercept analysis were utilized to perform sensitivity analysis.

Results

At the genus level, the results of MR analysis found that Coprococcus1 (OR: 1.0029, 95% CI: 1.0005–1.0054, p = 0.0202) was suggestively linked with an increased risk of VTE, while Slackia (odds ratio (OR): 0.9977, 95% confidence interval (CI): 0.9957–0.9998, p = 0.0298), Butyricicoccus (OR: 0.9971, 95% CI: 0.9945–0.9997, p = 0.0309), Eubacterium coprostanoligenes group (OR: 0.9972, 95% CI: 0.9946–0.9999, p = 0.0445), and Bacteroides (OR: 0.9964, 95% CI: 0.9932–0.9995, p = 0.0234) were suggestively associated with a reduced risk of VTE. No heterogeneity and horizontal pleiotropy was detected.

Conclusion

This study found that there were potential causal relationships between five gut microbiota and VTE. Our findings may provide new insights into the mechanisms of VTE.

Available only for authorised users

Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021;398:64–77. https://doi.org/10.1016/s0140-6736(20)32658-1.CrossRefPubMed

Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388:3060–73. https://doi.org/10.1016/s0140-6736(16)30514-1.CrossRefPubMed

Renner E, Barnes GD. Antithrombotic management of venous thromboembolism: JACC Focus Seminar. J Am Coll Cardiol. 2020;76:2142–54. https://doi.org/10.1016/j.jacc.2020.07.070.CrossRefPubMed

Zhang Q, Zhang X, Zhang J, Wang B, Tian Q, Meng X, et al. Vascular endothelial growth factor and the risk of venous thromboembolism: a genetic correlation and two-sample mendelian randomization study. Thromb J. 2022;20:67. https://doi.org/10.1186/s12959-022-00427-6.CrossRefPubMedPubMedCentral

Jin M, Qian Z, Yin J, Xu W, Zhou X. The role of intestinal microbiota in cardiovascular disease. 2019;23:2343–50. https://doi.org/10.1111/jcmm.14195

Fan Z, Xu S, Deng Y, Wei L, Yang J, Xing X. Disordered gut microbiota and alterations in the serum metabolome are associated with venous thromboembolism. Thromb Res. 2024;235:68–74. https://doi.org/10.1016/j.thromres.2024.01.022.CrossRefPubMed

Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Th Adv Gastroenterol. 2013;6:295–308. https://doi.org/10.1177/1756283x13482996.CrossRef

Arnold JW, Roach J, Azcarate-Peril MA. Emerging technologies for Gut Microbiome Research. Trends Microbiol. 2016;24:887–901. https://doi.org/10.1016/j.tim.2016.06.008.CrossRefPubMedPubMedCentral

Zhang Z, Chen H, Huang J, Zhang S, Li Z, Kong C, et al. Early administration of vancomycin inhibits pulmonary embolism by remodeling gut microbiota. 2023;13:537.

10.

Yang M, Luo P, Zhang F, Xu K, Feng R, Xu P. Large-scale correlation analysis of deep venous thrombosis and gut microbiota. 2022;9. https://doi.org/10.3389/fcvm.2022.1025918.

11.

Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where are we now and where are we going? Int J Epidemiol. 2015;44:379–88. https://doi.org/10.1093/ije/dyv108.CrossRefPubMed

12.

Qiu B, Shen Z, Yang D, Qin X, Ren W, Wang Q. Gut microbiota and common gastrointestinal diseases: a bidirectional two-sample mendelian randomized study. 2023;14:https://doi.org/10.3389/fmicb.2023.1273269

13.

Yan W, Ge Y, Wang L, Wang Y, He D. Causal relationship of gut microbiota with diabetic nephropathy: a mendelian randomization analysis. 2024;14:https://doi.org/10.3389/fmicb.2023.1281361

14.

Li H, Li C. Causal relationship between gut microbiota and type 2 diabetes: a two-sample mendelian. Randomization Study. 2023;14. https://doi.org/10.3389/fmicb.2023.1184734.

15.

Li Y, Fu R, Li R, Zeng J, Liu T, Li X et al. Causality of gut microbiome and hypertension: a bidirectional mendelian randomization study. 2023;10:https://doi.org/10.3389/fcvm.2023.1167346

16.

Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021;53:156–65. https://doi.org/10.1038/s41588-020-00763-1.CrossRefPubMedPubMedCentral

17.

Xie J, Huang H, Liu Z, Li Y, Yu C, Xu L, et al. The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive mendelian randomization study. Hepatology. 2023;77:949–64. https://doi.org/10.1002/hep.32728.CrossRefPubMed

18.

Bae SC, Lee YH. Vitamin D level and risk of systemic lupus erythematosus and rheumatoid arthritis: a mendelian randomization. Clin Rheumatol. 2018;37:2415–21. https://doi.org/10.1007/s10067-018-4152-9.CrossRefPubMed

19.

Huang S, Tian F, Yang X, Fang S, Fan Y, Bao J. Physical activity and systemic lupus erythematosus among European populations: a two-sample mendelian randomization study. Front Genet. 2021;12:784922. https://doi.org/10.3389/fgene.2021.784922.CrossRefPubMed

20.

Burgess S, Thompson SG. Interpreting findings from mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377–89. https://doi.org/10.1007/s10654-017-0255-x.CrossRefPubMedPubMedCentral

21.

Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some Invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304–14. https://doi.org/10.1002/gepi.21965.CrossRefPubMedPubMedCentral

22.

Xiang K, Wang P, Xu Z, Hu YQ, He YS, Chen Y, et al. Causal effects of Gut Microbiome on systemic lupus erythematosus: a two-sample mendelian randomization study. Front Immunol. 2021;12:667097. https://doi.org/10.3389/fimmu.2021.667097.CrossRefPubMedPubMedCentral

23.

Sun W, Zhang L, Liu W, Tian M, Wang X, Liang J, et al. Stroke and myocardial infarction: a bidirectional mendelian randomization study. Int J Gen Med. 2021;14:9537–45. https://doi.org/10.2147/ijgm.S337681.CrossRefPubMedPubMedCentral

24.

Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46:1985–98. https://doi.org/10.1093/ije/dyx102.CrossRefPubMedPubMedCentral

25.

Yang M, Wan X, Su Y, Xu K, Wen P, Zhang B, et al. The genetic causal relationship between type 2 diabetes, glycemic traits and venous thromboembolism, deep vein thrombosis, pulmonary embolism: a two-sample mendelian randomization study. Thromb J. 2024;22:33. https://doi.org/10.1186/s12959-024-00600-z.CrossRefPubMedPubMedCentral

26.

Sang N, Gao RC, Zhang MY, Wu ZZ, Wu ZG, Wu GC. Causal relationship between sleep traits and risk of systemic lupus erythematosus: a two-sample mendelian randomization study. Front Immunol. 2022;13:918749. https://doi.org/10.3389/fimmu.2022.918749.CrossRefPubMedPubMedCentral

27.

Luo S, Li W, Li Q, Zhang M, Wang X, Wu S et al. Causal effects of gut microbiota on the risk of periodontitis: a two-sample mendelian randomization study. 2023;13. https://doi.org/10.3389/fcimb.2023.1160993

28.

Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7. https://doi.org/10.7554/eLife.34408.

29.

Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693–8. https://doi.org/10.1038/s41588-018-0099-7.CrossRefPubMedPubMedCentral

30.

Hasan RA, Koh AY, Zia A. The gut microbiome and thromboembolism. Thromb Res. 2020;189:77–87. https://doi.org/10.1016/j.thromres.2020.03.003.CrossRefPubMedPubMedCentral

31.

Potere N, Abbate A, Kanthi Y, Carrier M, Toldo S, Porreca E et al. Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism. JACC: Basic Transl Sci. 2023;8:1245-61. https://doi.org/10.1016/j.jacbts.2023.03.017

32.

Kondo K, Suzuki Y, Ikeda Y, Umemura K. Genistein, an isoflavone included in soy, inhibits thrombotic vessel occlusion in the mouse femoral artery and in vitro platelet aggregation. Eur J Pharmacol. 2002;455:53–7. https://doi.org/10.1016/S0014-2999(02)02449-4.CrossRefPubMed

33.

Applová L, Karlíčková J, Říha M, Filipský T, Macáková K, Spilková J, et al. The isoflavonoid tectorigenin has better antiplatelet potential than acetylsalicylic acid. Phytomedicine. 2017;35:11–7. https://doi.org/10.1016/j.phymed.2017.08.023.CrossRefPubMed

34.

Langa S, Peirotén Á, Curiel JA, de la Bastida AR, Landete JM. Isoflavone metabolism by lactic acid Bacteria and its application in the development of fermented soy food with beneficial effects on human health. Foods. 2023;12:1293.

35.

Schröder C, Matthies A, Engst W, Blaut M, Braune A. Identification and expression of genes involved in the conversion of Daidzein and Genistein by the Equol-Forming bacterium Slackia isoflavoniconvertens. 2013;79:3494–502. https://doi.org/10.1128/AEM.03693-12

36.

Matthies A, Blaut M, Braune A. Isolation of a human intestinal bacterium capable of Daidzein and Genistein conversion. 2009;75:1740–4. https://doi.org/10.1128/AEM.01795-08

37.

Koupenova M, Kehrel BE, Corkrey HA, Freedman JE. Thrombosis and platelets: an update. Eur Heart J. 2017;38:785–91. https://doi.org/10.1093/eurheartj/ehw550.CrossRefPubMed

38.

Shin J-H, Kwon H-W, Rhee MH, Park H-J. Inhibitory effects of thromboxane A2 generation by ginsenoside ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release. J Ginseng Res. 2019;43:236–41. https://doi.org/10.1016/j.jgr.2017.12.007.CrossRefPubMed

39.

Muñoz Y, Garrido A, Valladares L. Equol is more active than soy isoflavone itself to compete for binding to thromboxane A(2) receptor in human platelets. Thromb Res. 2009;123:740–4. https://doi.org/10.1016/j.thromres.2008.07.011.CrossRefPubMed

40.

Li L, Ma L, Fu P. Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Devel Ther. 2017;11:3531–42. https://doi.org/10.2147/dddt.S150825.CrossRefPubMedPubMedCentral

41.

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189–200. https://doi.org/10.1080/19490976.2015.1134082.CrossRefPubMedPubMedCentral

42.

Sam QH, Ling H, Yew WS, Tan Z, Ravikumar S, Chang MW et al. The Divergent Immunomodulatory effects of short chain fatty acids and medium chain fatty acids. Int J Mol Sci. 2021;22:6453.

43.

Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31:817–44. https://doi.org/10.1210/er.2009-0030.CrossRefPubMed

44.

Nastasi C, Candela M, Bonefeld CM, Geisler C, Hansen M, Krejsgaard T, et al. The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci Rep. 2015;5:16148. https://doi.org/10.1038/srep16148.CrossRefPubMedPubMedCentral

45.

Wang Z, Fang C, Yao M, Wu D, Chen M, Guo T et al. Research progress of NF-κB signaling pathway and thrombosis. 2023;14:https://doi.org/10.3389/fimmu.2023.1257988

46.

Pedersen SS, Prause M, Williams K, Barrès R, Billestrup N. Butyrate inhibits IL-1β-induced inflammatory gene expression by suppression of NF-κB activity in pancreatic beta cells. J Biol Chem. 2022;298:102312. https://doi.org/10.1016/j.jbc.2022.102312.CrossRefPubMedPubMedCentral

47.

Lu H, Xu X, Fu D, Gu Y, Fan R, Yi H, et al. Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis. Cell Host Microbe. 2022;30:1139–50.e7. https://doi.org/10.1016/j.chom.2022.07.003.CrossRefPubMed

48.

Jia J, Nie L, Liu Y. Butyrate alleviates inflammatory response and NF-κB activation in human degenerated intervertebral disc tissues. Int Immunopharmacol. 2020;78:106004. https://doi.org/10.1016/j.intimp.2019.106004.CrossRefPubMed

49.

Liu H, Sun J, Jiang S, Jiao N, Huang L, Yuan X, et al. Effects of dietary isoleucine supplementation on the production performance, health status and cecal microbiota of arbor acre broiler chickens. Microorganisms. 2023;11. https://doi.org/10.3390/microorganisms11020236.

50.

Takada T, Watanabe K, Makino H, Kushiro A. Reclassification of Eubacterium desmolans as Butyricicoccus desmolans comb. nov., and description of Butyricicoccus faecihominis sp. nov., a butyrate-producing bacterium from human faeces. 2016;66:4125–31. https://doi.org/10.1099/ijsem.0.001323

51.

Boesmans L, Valles-Colomer M, Wang J, Eeckhaut V, Falony G, Ducatelle R, et al. Butyrate producers as potential next-generation probiotics: safety assessment of the administration of < i > Butyricicoccus pullicaecorum to. Healthy Volunteers. 2018;3. https://doi.org/10.1128/msystems.00094-18.

52.

Kim HS, Kim JS, Suh MK, Eom MK, Lee JH, Park SH, et al. Bacteroides humanifaecis sp. nov., isolated from faeces of healthy Korean. Arch Microbiol. 2022;204:357. https://doi.org/10.1007/s00203-022-02967-x.CrossRefPubMed

53.

Xu J, Wang R, Zhang H, Wu J, Zhu L, Zhan X. In vitro assessment of prebiotic properties of oligosaccharides derived from four microbial polysaccharides. LWT. 2021;147:111544. https://doi.org/10.1016/j.lwt.2021.111544.CrossRef

54.

Tan H, Zhao J, Zhang H, Zhai Q, Chen W. Novel strains of Bacteroides fragilis and Bacteroides ovatus alleviate the LPS-induced inflammation in mice. Appl Microbiol Biotechnol. 2019;103:2353–65. https://doi.org/10.1007/s00253-019-09617-1.CrossRefPubMed

55.

Huang X-y, Zhang Y-h, Yi S-y, Lei L, Ma T, Huang R et al. Potential contribution of the gut microbiota to the development of portal vein thrombosis in liver cirrhosis. 2023;14:https://doi.org/10.3389/fmicb.2023.1217338

56.

Xiong LL, Mao ML, Shu QL. A preliminary study on the diversity of butyrate-producing bacteria in response to the treatment of depression with Xiaoyaosan. 2022;75:844–56. https://doi.org/10.1111/lam.13737

57.

Bai D, Zhao J, Wang R, Du J, Zhou C, Gu C, et al. Eubacterium coprostanoligenes alleviates chemotherapy-induced intestinal mucositis by enhancing intestinal mucus barrier. Acta Pharm Sinica B. 2024;14:1677–92. https://doi.org/10.1016/j.apsb.2023.12.015.CrossRef

58.

Altemani F, Barrett HL, Gomez-Arango L, Josh P, David McIntyre H, Callaway LK, et al. Pregnant women who develop preeclampsia have lower abundance of the butyrate-producer coprococcus in their gut microbiota. Pregnancy Hypertens. 2021;23:211–9. https://doi.org/10.1016/j.preghy.2021.01.002.CrossRefPubMed

59.

Yang R, Shan S, Shi J, Li H, An N, Li S, et al. Coprococcus eutactus, a potent probiotic, alleviates colitis via acetate-mediated IgA response and microbiota restoration. J Agric Food Chem. 2023;71:3273–84. https://doi.org/10.1021/acs.jafc.2c06697.CrossRef

60.

Gao Y, Liu L, Cui Y, Zhang J, Wu X. The causality of gut microbiota on onset and progression of sepsis: a bi-directional mendelian. Randomization Anal. 2024;15. https://doi.org/10.3389/fimmu.2024.1266579.

61.

Shang W, Zhang S, Qian H, Huang S, Li H, Liu J et al. Gut microbiota and sepsis and sepsis-related death: a mendelian randomization investigation. 2024;15:https://doi.org/10.3389/fimmu.2024.1266230

62.

Gao J, Shao S, Shen Y. Causal effects of gut microbiota on risk of interstitial cystitis: a two-sample mendelian randomization study. 2024;15. https://doi.org/10.3389/fmicb.2024.1434117.

63.

Jiang P, Li C, Su Z, Chen D, Li H, Chen J, et al. Mendelian randomization study reveals causal effects of specific gut microbiota on the risk of interstitial cystitis/bladder pain syndrome (IC/BPS). Sci Rep. 2024;14:18405. https://doi.org/10.1038/s41598-024-69543-9.CrossRefPubMedPubMedCentral

Title: Causal effect of gut microbiota on venous thromboembolism: a two-sample mendelian randomization study
Authors: Linfeng Xi
Hongyi Wang
Jie Du
Anqi Liu
Jianping Wang
Yifei Ni
Shuai Zhang
Wanmu Xie
Min Liu
Chen Wang
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Thrombosis Journal / Issue 1/2024
Electronic ISSN: 1477-9560
DOI: https://doi.org/10.1186/s12959-024-00676-7

Laboratory and clinical haemostatic aberrations in primary dermatologic disease: A review

Open Access
Review

Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban

Open Access
Rivaroxaban
Original Research

Integrated proteomic and metabolomic profiling of lymph after trauma-induced hypercoagulopathy and antithrombotic therapy

Open Access
Clopidogrel
Original Research

Reduced mortality associated with pulmonary embolism response team consultation for intermediate and high-risk pulmonary embolism: a retrospective cohort study

Open Access
Original Research

Cancer incidence and mortality after a first-ever venous thrombosis: a cohort study in northern Sweden

Open Access
Research

Thrombosis-related characteristics of pregnant women with antithrombin deficiency, protein C deficiency and protein S deficiency in Japan

Open Access
Thrombosis
Original Research

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content